Compositions and methods for the diagnosis of systemic autoimmune disease
AssigneeInova Diagnostics, Inc.
InventorMichael Mahler
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the field of molecular biology and immunology. More specifically. the present disclosure provides compositions and methods for detecting anti-Th/To autoantibodies in the serum of subject with a systemic autoimmune disease, such as systemic sclerosis (SSc).
Claims21
1-86. (canceled)
A method for detecting an anti-Th/To antibody in a subject comprising:
- a) contacting a sample from the subject with a purified peptide comprising at least seven contiguous amino acids of an epitope derived from a subunit of a Th/To complex, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 14, 15, 21, 35, 36, 49, 53, 60-62. 65, 66, 71, 72, and 77-97 or a variant thereof, wherein the purified peptide forms a complex with an anti-Th/To antibody, and
- b) detecting the presence or absence of the anti-Th/To antibody-purified peptide complex in the sample, wherein said anti-Th/To antibody comprises an anti-Rpp25 antibody, an anti-Rpp38 antibody, an anti-hPop1 antibody, or any combination thereof.
A method of diagnosing systemic sclerosis (SSc) in a human subject suspected of having SSc, comprising:
- a) contacting a sample from the subject with a purified peptide comprising at least seven contiguous amino acids of an epitope derived from a subunit of a Th/To complex, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 14, 15, 21, 35, 36, 49, 53, 60-62. 65, 66, 71, 72, and 77-97 or a variant thereof, wherein the purified peptide forms a complex with an anti-Th/To antibody, and
- b) detecting the presence or absence of the anti-Th/To antibody-purified peptide complex in the sample, wherein the presence of the anti-Th/To antibody-purified peptide complex in the sample indicates that the subject has SSc;
- said anti-Th/To antibody comprising an anti-Rpp25 antibody, an anti-Rpp38 antibody, an anti-hPop1 antibody, or any combination thereof.
A method of determining the prognosis of systemic sclerosis (SSc) in a human subject, comprising:
- a) contacting a sample from the subject with a purified peptide comprising at least seven contiguous amino acids of an epitope derived from a subunit of a Th/To complex, wherein said epitope comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 14, 15, 21, 35, 36, 49, 53, 60-62. 65, 66, 71, 72, and 77-97 or a variant thereof, wherein the purified peptide forms a complex with an anti-Th/To antibody, and
- b) detecting the presence or absence of the anti-Th/To antibody-purified peptide complex in the sample, wherein the presence of the anti-Th/To antibody-purified peptide complex in the sample indicates the course of SSc progression in the human subject;
- said anti-Th/To antibody comprising an anti-Rpp25 antibody, an anti-Rpp38 antibody, an anti-hPop1 antibody, or any combination thereof.
A purified peptide comprising an epitope derived from ribonuclease P protein subunit p38 (Rpp38) subunit of Th/To complex, wherein said epitope comprises an amino acid sequence of SEQ ID NO:102.
Dependencies are inferred from the claim text.